Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
J Neurol Sci. 2012 Feb 15;313(1-2):110-4. doi: 10.1016/j.jns.2011.09.012. Epub 2011 Oct 10.
The prognosis in ischemic stroke is poor in diabetic patients. However, scant research has so far been done on the predisposing factors associated with poor outcomes.
We prospectively investigated the background characteristics and prognosis at 3 months in 241 consecutive diabetic patients having their first ischemic stroke (153 males, 88 females, mean age ± SD, 71 ± 10 years). Poor functional outcome was defined as modified Rankin scale ≥ 3 at 3 months after onset.
Univariate analysis showed that age, dementia, initial National Institutes of Health Stroke Scale (NIHSS) score, systolic blood pressure on admission, proteinuria, stroke subtype, and prior use of angiotensin receptor blocker (ARB) were significantly related to an outcome at 3 months after onset. A multivariate logistic regression analysis showed that age (odds ratio (OR) 1.07, 95% confidence interval (CI) 1.01 to 1.13, p=0.017, per 1-year increase), NIHSS score (OR 1.22, 95% CI 1.12 to 1.35, p<0.001, per 1-score increase), and proteinuria (OR 4.22, 95% CI 1.71 to 10.92, p=0.002) were significantly and independently associated with poor clinical outcome after ischemic stroke in diabetic patients. Conversely, prior use of ARB (OR 0.28, 95% CI 0.09 to 0.79, p=0.023) was associated with a better outcome.
In diabetic patients, proteinuria was independently associated with a poor clinical outcome after ischemic stroke, whereas the prior use of ARB appeared to be beneficial.
糖尿病患者发生缺血性脑卒中的预后较差。然而,目前针对与不良预后相关的易患因素的研究甚少。
我们前瞻性研究了 241 例首次发生缺血性脑卒中的连续糖尿病患者(男性 153 例,女性 88 例,平均年龄±标准差,71±10 岁)的背景特征和 3 个月时的预后。不良功能结局定义为发病后 3 个月时改良 Rankin 量表评分≥3 分。
单因素分析显示,年龄、痴呆、初始国立卫生研究院卒中量表(NIHSS)评分、入院时收缩压、蛋白尿、卒中亚型和血管紧张素受体阻滞剂(ARB)的既往使用与发病后 3 个月的结局显著相关。多变量 logistic 回归分析显示,年龄(比值比(OR)1.07,95%置信区间(CI)1.01 至 1.13,p=0.017,每增加 1 岁)、NIHSS 评分(OR 1.22,95%CI 1.12 至 1.35,p<0.001,每增加 1 分)和蛋白尿(OR 4.22,95%CI 1.71 至 10.92,p=0.002)与糖尿病患者缺血性脑卒中后的不良临床结局显著独立相关。相反,ARB 的既往使用(OR 0.28,95%CI 0.09 至 0.79,p=0.023)与较好的结局相关。
在糖尿病患者中,蛋白尿与缺血性脑卒中后的不良临床结局独立相关,而 ARB 的既往使用似乎有益。